Friday, 20 October 2017 - 5:01

Top stories

News of the week

FDA approves Yescarta, Kite/Gilead’s CAR-T therapy

Kite, part of Gilead group, has announced that FDA has approved Yescarta (axicabtagene ciloleucel), a CAR-T (chimeric antigen receptor T cell) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines…

Approvals

Procedures / New drug and device authorizations / Recommendations

FDA approves Yescarta, Kite/Gilead’s CAR-T therapy

Kite, part of Gilead group, has announced that FDA has approved Yescarta (axicabtagene ciloleucel), a CAR-T (chimeric antigen receptor T cell) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines…

Companies

Healthcare market news

Chiesi signs $370m-worth license agreement with Protalix

Israel-based Protalix Biotherapeutics today announced it has signed a license agreement worth $370m with Chiesi Farmaceutici over pegunigalsidase alfa (PRX-102). Under the agreement, Protalix will sell Chiesi the the worldwide, Ex-US commercialization rights to PRX-102, and will receive $25m upfront,…

Chemistry

Market and Technology

BASF strikes its largest acquisition ever

Germany-based BASF some days ago announced its largest acquisition ever: indeed, the Ludwigshafen-based group last Friday reported it had successfully completed the negotiations to acquire a significant part of Bayer’s seed business for €5.9bn–that is 15x EBITDA. The acquired asset…

M&A

Mergers & Acquisitions

BASF strikes its largest acquisition ever

Germany-based BASF some days ago announced its largest acquisition ever: indeed, the Ludwigshafen-based group last Friday reported it had successfully completed the negotiations to acquire a significant part of Bayer’s seed business for €5.9bn–that is 15x EBITDA. The acquired asset…

Nutraceuticals

Food supplements

Asthma, evidences of benefit from vitamin D in The Lancet Respiratory Medicine

The review The Lancet Respiratory Medicine has reported the results from a research conducted by the Queen Mary University of London, demonstrating that oral vitamin D, associated to the standard therapy for asthma, can help halve the risk of asthma…

Pathology

Latest developments

N4 Pharma’s shares rise 7% thanks to a reformulation of sildenafil (Viagra)

N4 Pharma’s shares (London) today rose over 7% as trading opened, as the company issued a release announcing the publication of the PCT Patent Application in respect of its reformulation of sildenafil (Viagra). N4 Pharma has developed an original business…

Safety

News on Product Safety

FDA issues warning about Intercept’s Ocaliva after 19 patients died

The FDA has officially warned doctors about the risks from Intercept Pharmaceuticals’ Ocaliva (obeticholic acid), after 19 patients on Intercept’s drug, developed to treat PBC (Primary Biliary Cholangitis) had died. The FDA, anyway, has specified that the deaths have occurred…

Trials

Preclinical Trials / Clinical Trials / Epidemiology

Titan’s ProNeura in Parkinson: first patient treated in a Phase I/II study

Titan Pharmaceuticals is a company developing new therapeutics using its technology called ProNeura, a long-term, continuous drug delivery system. The company has announced that the first patient has been treated in a Phase I/II trial of the company’s ropinirole release…